Decimmune Therapeutics decimmune.com


Public lists: Pharma Startups (6570)

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. This pathway, dubbed N2, can initiate a cascade of tissue damaging events leading to loss o...Show all

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM...Show all

Company (Alive / Active)

Phone: 617-278-6655

Fax:

47 Thrndike Street
Suite B1-1
Cambridge, 02141
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Decimmune Therapeutics $10.5M Oct 3, 2014
VLST Corporation $67.9M Aug 7, 2013
Bayhill Therapeutics $97.4M Jun 11, 2011
See all 17 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Decimmune Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors

Competitors

Company Status Description Investors
See all 17 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Humanized, anti-n2 antibodies Mar 12, 2014 Aug 09, 2016 Patent
Humanized anti-n2 antibodies and methods of treating ischemia-reperfusion injury Mar 12, 2014 Jan 26, 2016 Patent
Anti-inflammatory antibodies and uses therefor Nov 05, 2012 Jun 30, 2015 Patent
Anti-inflammatory antibodies and uses therefor Dec 07, 2010 Dec 04, 2012 Patent
Humanized, anti-n2 antibodies Jun 29, 2016 Application
See all 6 patents